Sensorium Therapeutics to Present SNTX-2643 Mechanistic Data and Phase 1a Study Design at ASCP 2026

SNTX-2643 is a novel, investigational, state-selective serotonin transporter modulator being developed for anxiety disorders Company also announces appointment of Cole Brown, M.D., as Chief Medical Officer and formation of a Clinical Advisory Board CAMBRIDGE, Mass., May 27, 2026...